ThromboGenics presenting ophthalmic research findings at Congress of the Academia Ophthalmologica Belgica

8 Jan 2016

Leuven, January 8, 2016 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the Company will be presenting two scientific posters at the Congress of the Academia Ophthalmologica Belgica, January 11-13th in Brussels, Belgium.

 

  • Dr. Tine Van Bergen of ThromboGenics will present a poster entitled: PlGF inhibition is as efficacious as VEGF-Trap in reducing scar formation after glaucoma surgery Grant 2014-2015: FRO. The study compares the effect of aflibercept (VEGF-Trap) to PIGF inhibition (5D11D4) on the surgical outcome in a murine model of glaucoma filtration surgery.

 

  •  Dr. Koen Willekens of UZ, Ophthalmology, Leuven will present a poster entitled: Robot assisted retinal vein cannulation. The poster covers a study aimed at performing and reporting on in vivo retinal vein cannulations with the help of a dedicated robot. Robot-assisted retinal vein cannulations can overcome practical limitations in the local delivery of antithrombotic drugs (such as ocriplasmin), an experimental therapy for retinal vein occlusions.

 

Dr. Patrik De Haes, ThromboGenics’ CEO, said: “We are pleased to have the opportunity to share our research at the Congress of the Academia Ophthalmologica Belgica this year. The studies being presented demonstrate our ongoing commitment to high-quality technological research in the field of ophthalmology.”